Acceleration of Specific Cancer Therapies Planned Through Project
The STSI (Scripps Translational Science Institute based in San Diego, California has recently joined a countrywide conference of research bodies that is led by the JAX (Jackson Laboratory). The JAX is creating a library that will document all known primary brain tumours. The JAX is doing this with the aim of the future development of incredibly specific cancer therapy treatments.
As a member of this conference, the STSI will facilitate for the provision of solid human tumour samples to the Jackson Laboratory, this will be then grafted into mouse models in order to enable further research and scientific analysis. These models will be available to scientists of the STSI and will be able to perform studies on ways of better comprehending and combatting cancer.
The initial genomic characterisation of the tumour samples will be performed by scientists from the Jackson Labs, the resulting information or data will then be shared freely with laboratories that are also partaking in this project. The STSI is a non profit organisation and this project will also be done in collaboration with the other San Diego based Institution, The Scripps Research Institute.
The Primary Human Tumour Consortium was launched by the Jackson Laboratories in the year 2009. The Swedish neuroscience institute located in Seattle, the UC Davis Cancer Centre and the University Of Florida are other additional institutions taking part in this consortium.
Mouse models that have the ability to accept additional human tumours will prove to be a very innovative method of the development and testing of cancer treatments. This is because it is possible to create mouse models of nearly any and all forms of cancer; this will enable the provision of a much more specialised way of discovering novel cancer treatments.
The primary health tumour consortium based at the JAX in California requires further search and health care partners in order to increase the pace at which the tumour library resource will reach completion. To this very day the consortium has successfully managed to graft one hundred and seventy two tumours, with tumours from the brain, bladder, pancreas, lung, colon, breast and kidney.